Day 0, within the safety reporting process, is the date on which the regulatory deadline for an expedited reportable case begins. According to ICH E2D, this is generally the day when any employee of the marketing authorization holder first receives a report that meets the minimum criteria and the requirements for expedited reporting. The term thus marks the start of a deadline, not the time of the event in the patient.<\/p>\n
The relevant receipt can occur within a pharmacovigilance department, but also with other employees of the marketing authorization holder. For Day 0, it does not matter when a case is internally forwarded to the safety team or entered into a safety database. What is crucial is the first receipt of information by the marketing authorization holder, provided it meets the necessary criteria for an expedited report.<\/p>\n
According to ICH E2D, the minimum information for a case includes an identifiable reporter, an identifiable patient, an adverse reaction, and a suspected medicinal product. If any of these elements are missing, the case is considered incomplete; the marketing authorization holder should follow up on the missing information with due diligence. A vague reference without an identifiable patient therefore does not trigger the same deadline mechanism as a validatable case.<\/p>\n
For serious and unexpected adverse drug reactions, ICH E2D specifies a general requirement for expedited reporting as soon as possible and no later than 15 calendar days after receipt of the initial information. This timeframe does not replace a review of the applicable legal provisions. Its function in the concept of Day 0 is to make the precisely documented starting point of the calculation visible.<\/p>\n
A case initially submitted is rarely complete as soon as it is created. Supplementary medically relevant information can specify diagnoses, add an outcome, correct a dose, or change the severity. If relevant follow-up information is received for an already reported case, the deadline for the follow-up report begins anew according to ICH E2D.<\/p>\n
Particular attention is required for a case that was initially not subject to expedited reporting. Follow-up information may show that it needs to be reclassified, for example, because an event originally not serious is now assessed as serious. At this moment, the access date of the first, non-reportable information does not retroactively become the starting point; the qualifying state of knowledge determines the start of the relevant deadline.<\/p>\n
For the case file, it must therefore remain traceable which information was received when and by whom, what assessment was possible at that time, and which follow-up information changed the classification. A mere database date is insufficient if it obscures the actual initial receipt or the receipt of the crucial new information.<\/p>\n
Day 0 is not the same as follow-up. Follow-up refers to the process of obtaining and processing missing or new information for a case. Day 0, on the other hand, refers to the specific date from which a reporting deadline is calculated. In the event of a medically relevant addition, both terms coincide because the follow-up can trigger a new deadline for the subsequent report, but they remain functionally distinct.<\/p>\n
Likewise, an event date, a hospital admission date, or the date of medical confirmation is not automatically Day 0. These dates describe the clinical course. The term anchors the regulatory process to the receipt of the qualified case by the marketing authorization holder.<\/p>\n
The existing glossary entry for follow-up helps classify the tracking process. For case processing, it must also be clear which received detail controls the timing of the electronic submission. Without this distinction, deadlines could be incorrectly calculated from the time of entry or from the first query.<\/p>\n
In clinical trials, safety information from investigational sites, Medical Information, program teams, and electronic channels must reach an auditable intake documentation without delay. The timestamp of the site submission alone does not answer when the sponsor or marketing authorization holder actually received the validatable case. Processes therefore require clear escalation pathways for serious events, documented validation, and rules for handling subsequently submitted findings.<\/p>\n
Full-service CROs like Mediconomics support Day 0 management through case triage, documentation of initial receipt, verification of minimum criteria, and timely coordination of medical follow-up inquiries. In the interplay of safety case processing, investigational site, and data management, they can also transparently record when additional information triggered a new classification and thus the deadline for a follow-up report.<\/p>\n
Does Day 0 only begin when the pharmacovigilance department sees the case?<\/strong><\/p>\n No. ICH E2D refers to the first receipt by any personnel of the marketing authorization holder, provided the report meets the minimum criteria and requires expedited reporting.<\/p>\n Does every addition to a case initiate a new deadline?<\/strong><\/p>\n For the renewed start of a deadline, ICH E2D specifies medically relevant additional information for an already reported case. Purely administrative corrections without significance for the safety assessment are to be distinguished from this.<\/p>\n What happens if the initial report does not appear serious?<\/strong><\/p>\n If a case is reclassified, for example, from non-serious to serious, due to follow-up information, it can only then meet the criteria for expedited reporting. The receipt of this crucial information is decisive for the new deadline.<\/p>\n Day 0, within the safety reporting process, is the date on which the regulatory deadline for an expedited reportable case begins. According to ICH E2D, this is generally the day when any employee of the marketing authorization holder first receives a report that meets the minimum criteria and the requirements for expedited reporting. The term […]<\/p>\n","protected":false},"author":10,"featured_media":0,"parent":0,"template":"","meta":{"_acf_changed":false,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"glossary-cat":[23],"class_list":["post-8084","glossary","type-glossary","status-publish","hentry","glossary-cat-pharmakovigilanz"],"acf":[],"related_terms":"","external_url":"","internal_reference_id":"","_links":{"self":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary\/8084","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary"}],"about":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/types\/glossary"}],"author":[{"embeddable":true,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/users\/10"}],"version-history":[{"count":0,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary\/8084\/revisions"}],"wp:attachment":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/media?parent=8084"}],"wp:term":[{"taxonomy":"glossary-cat","embeddable":true,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary-cat?post=8084"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Regulatory References<\/h2>\n
\n